Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company: Observational study in Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer (400 participants)
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company: Observational study in Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer (400 participants). Its enrollment of 400 is above the median of 80 (87th percentile). Dated 27 days ago, it is in the active follow-up window. Score 60/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 400 · 87th percentile of 9,177 ClinicalTrialStartPulse records · 5.0x the median
Free preview: all 13 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | TROPION Breast Respond in 1L TNBC |
| NCT ID | NCT07867470 |
| Phase | Observational |
| Status | not yet recruiting |
| Conditions | Unresectable Triple-negative Breast Cancer; Metastatic Triple-negative Breast Cancer |
| Intervention types | drug |
| Target enrollment | 400 |
| Posted | 2026-10-09 |
| Planned start | 2027-03-01 |
| Event | Newly registered study |
| Event date | 2026-10-09 |
| enrollment percentile | 87th of 9,177 (median 80, 5.0x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-09
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company and 6,823 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,823
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company's enrollment: 87th percentile of 9,177 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,364,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
60 / 100 Score
- Industry sponsor (buys outsourced services).
- 400 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company?
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company registered a Observational study (NCT07867470) in Unresectable Triple-negative Breast Cancer targeting 400 participants, posted 2026-10-09.
How does Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company compare to other ClinicalTrialStartPulse records?
Its enrollment of 400 sits in the upper half (87th percentile) of 9,177 records; the median is 80. It is 27 days old, still within a typical 45-day follow-up window.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | NONUS | 400 | 87th | 2026-10-09 |
| AstraZeneca | NONUS | 440 | 88th | 2026-11-04 |
| AstraZeneca | NONUS | 200 | 77th | 2026-11-04 |
| Janssen Research & Development, LLC | NONUS | 162 | 72nd | 2026-11-04 |
Related records
ClinicalTrialStartPulse: Observational ClinicalTrialStartPulse: Outside the US only
How to monitor Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company and peer observational records
Get new ClinicalTrialStartPulse records like Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.